Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

pharmacosmos a.s. - ferric derisomaltose 417 mg/ml - eq. iron 100 mg/ml - solution for injection/infusion - 100 mg/ml - ferric derisomaltose 417 mg/ml - iron, parenteral preparations

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

pharmacosmos a.s. - ferric derisomaltose 417 mg/ml - eq. iron 100 mg/ml - solution for injection/infusion - 100 mg/ml - ferric derisomaltose 417 mg/ml - iron, parenteral preparations

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

pharmacosmos a.s. - ferric derisomaltose 417 mg/ml - eq. iron 100 mg/ml - solution for injection/infusion - 100 mg/ml - ferric derisomaltose 417 mg/ml - iron, parenteral preparations

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

pharmacosmos a.s. - ferric derisomaltose 417 mg/ml - eq. iron 100 mg/ml - solution for injection/infusion - 100 mg/ml - ferric derisomaltose 417 mg/ml - iron, parenteral preparations

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

pharmacosmos a.s. - ferric derisomaltose 417 mg/ml - eq. iron 100 mg/ml - solution for injection/infusion - 100 mg/ml - ferric derisomaltose 417 mg/ml - iron, parenteral preparations

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

virbac (australia) pty ltd - ferric chloride - unknown - ferric chloride mineral-iron active 0.0 - active constituent

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

ausrichter pty ltd - ferric hydroxide sucrose compound - unknown - ferric hydroxide sucrose compound ungrouped active 0.0 - active constituent

United States - English - NLM (National Library of Medicine)

actavis pharma, inc. - sodium ferric gluconate complex (unii: cc9149u2qx) (ferric cation - unii:91o4lml611) - ferric cation 12.5 mg in 1 ml - sodium ferric gluconate complex in sucrose injection is indicated for the treatment of iron deficiency anemia in adult patients and in pediatric patients age 6 years and older with chronic kidney disease receiving hemodialysis who are receiving supplemental epoetin therapy. - known hypersensitivity to sodium ferric gluconate or any of its components. pregnancy category b there are no adequate and well-controlled studies with sodium ferric gluconate complex in sucrose injection in pregnant women. reproduction studies have been performed in mice at doses up to 100 mg/kg/day (300 mg/m2 /day) and in rats at up to 20 mg/kg/day (120 mg/m2 /day). the doses in mice and rats are 4 and 1.5 times the human dose of 125 mg/day (77 mg/m2 /day) on a body surface area basis and have revealed no evidence of harm to the fetus due to sodium ferric gluconate complex in sucrose injection. because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly need

United States - English - NLM (National Library of Medicine)

actavis pharma, inc. - sodium ferric gluconate complex (unii: cc9149u2qx) (ferric cation - unii:91o4lml611) - ferric cation 12.5 mg in 1 ml - sodium ferric gluconate complex in sucrose injection is indicated for the treatment of iron deficiency anemia in adult patients and in pediatric patients age 6 years and older with chronic kidney disease receiving hemodialysis who are receiving supplemental epoetin therapy. - known hypersensitivity to sodium ferric gluconate or any of its components. pregnancy category b there are no adequate and well-controlled studies with sodium ferric gluconate complex in sucrose injection in pregnant women. reproduction studies have been performed in mice at doses up to 100 mg/kg/day (300 mg/m2 /day) and in rats at up to 20 mg/kg/day (120 mg/m2 /day). the doses in mice and rats are 4 and 1.5 times the human dose of 125 mg/day (77 mg/m2 /day) on a body surface area basis and have revealed no evidence of harm to the fetus due to sodium ferric gluconate complex in sucrose injection. because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly ne

United States - English - NLM (National Library of Medicine)

ropack inc. - ferric pyrophosphate citrate (unii: uby79oco9g) (ferric cation - unii:91o4lml611) - ferric cation 272 mg in 272 mg - triferic is an iron replacement product indicated for the replacement of iron to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease (hdd-ckd). triferic is not intended for use in patients receiving peritoneal dialysis. triferic has not been studied in patients receiving home hemodialysis. none risk summary there are no data with triferic use in pregnant women to inform a drug-associated risk. no teratogenicity was observed in animal reproduction studies with administration of ferric pyrophosphate citrate to pregnant rats and rabbits during organogenesis at doses 96 and 128 times, respectively, the maximum recommended human dose (mrhd) of 27.2 mg per dialysis [see data]. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%–4% and 15%–20%, respectively. data animal data in a fertility and early embryonic development study in female rats, the maternally toxic ferric pyrophosphate citra